Mark Cobbold

Mark Cobbold has an extensive work experience in the field of oncology and immunology. Mark is currently working as the VP Oncology Early Discovery at AstraZeneca since September 2019. Prior to this, they were a Scientific Co-Founder at GigaMune, Gritstone Oncology, and Revitope, all in the years 2019, 2015, and 2014 respectively. Mark has also held the position of Associate Member at Broad Institute from September 2015 to September 2019. In addition, they have served as an Associate Professor of Medicine at Harvard University and Massachusetts General Hospital from June 2015 to September 2019. Before that, Mark was a Scientific Co-Founder at PhosImmune, Inc. and Serascience from September 2012 to June 2015 and from May 2011 to June 2015 respectively. Mark initially started their career at the University of Birmingham, where they held the positions of Reader in Translational Immunology from March 2014 to May 2015 and Senior Clinical Research Fellow (Tumour Immunology) from September 2009 to March 2014.

Mark Cobbold earned their PhD in Immunology / Immunotherapy from the University of Birmingham from 2000 to 2003.